Cargando…

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

The recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL amyloidosis-unrelated factors may impact mortality. In this study, we evaluated survival trends and primary causes of death among 2337...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staron, Andrew, Zheng, Luke, Doros, Gheorghe, Connors, Lawreen H., Mendelson, Lisa M., Joshi, Tracy, Sanchorawala, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338947/ https://www.ncbi.nlm.nih.gov/pubmed/34349108 http://dx.doi.org/10.1038/s41408-021-00529-w

Ejemplares similares

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure
por: Tahir, Usman A., et al.
Publicado: (2019)

Features of atrial fibrillation in wild‐type transthyretin cardiac amyloidosis: a systematic review and clinical experience
por: Mints, Yuliya Y., et al.
Publicado: (2018)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Preclinical Development of siRNA Therapeutics for AL Amyloidosis
por: Hovey, Beth M., et al.
Publicado: (2011)

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
por: Havasi, Andrea, et al.
Publicado: (2022)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent
por: Adebayo, Adebanke L., et al.
Publicado: (2023)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report
por: Verma, Karina, et al.
Publicado: (2023)

Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2021)

Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant
por: Prokaeva, Tatiana, et al.
Publicado: (2017)

Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis
por: Leung, Amy, et al.
Publicado: (2013)

The Diagnosis, Natural History and Treatment of Amyloidosis: The Goulstonian Lecture 1995
por: Hawkins, P N
Publicado: (1997)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

AL Amyloidosis
por: Desport, Estelle, et al.
Publicado: (2012)

Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation
por: Lohrmann, Graham, et al.
Publicado: (2020)

Longitudinal strain in the management of cardiac AL amyloidosis: do we need it?
por: Rapezzi, Claudio, et al.
Publicado: (2021)

Natural history in America. From Mark Catesby to Rachel Carson
Publicado: (1978)

Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021)

Natural history and survival rate of familial amyloidosis with polyneuropathy: A nationwide databank
por: Tseng, Wei‐Hsiang, et al.
Publicado: (2023)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis
por: Lee Chuy, Katherine, et al.
Publicado: (2020)

Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2019)

Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis
por: Abdallah, Al-Ola, et al.
Publicado: (2012)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
por: Fraser, Cameron S., et al.
Publicado: (2022)

Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
por: Ruberg, Frederick L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nd4qtqgh3ben1qqgsn6k4kvmn5